U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H16N2.ClH
Molecular Weight 224.73
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IPIDACRINE MONOHYDROCHLORIDE

SMILES

Cl.NC1=C2CCCCC2=NC3=C1CCC3

InChI

InChIKey=FERZJAONQGPFCU-UHFFFAOYSA-N
InChI=1S/C12H16N2.ClH/c13-12-8-4-1-2-6-10(8)14-11-7-3-5-9(11)12;/h1-7H2,(H2,13,14);1H

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.1998.tb00067.x/pdf

Ipidacrine (Neiromidin) is a drug first synthesized by the National Research Center for Biologically Active Compounds in the Russian Federation. Neuromidin has a direct stimulating effect on the conduct of the pulse along the nerve fibers, interneuronal and neuromuscular synapses of the CNS and peripheral nervous system. Pharmacological action neuromidin is based on a combination of two mechanisms of action: blockade of potassium channels of the membrane of neurons and muscle cells; reversible inhibition of cholinesterase in synapses. Neuromidin enhances the effect on smooth muscle acetylcholine not only, but epinephrine, serotonin, histamine and oxytocin. It has the following pharmacological effects: - Improve and stimulate impulse conduction in the nervous system and neuromuscular transmission; - Enhances contractility of smooth muscle organs under the influence of acetylcholine agonists, adrenaline, serotonin, histamine and oxytocin receptors, with the exception of potassium chloride; - Improves memory, slows progressive course of dementia. In preclinical studies Neuromidin is not teratogenic, embryotoxic, mutagenic, carcinogenic and immunotoxic action, had no effect on the endocrine system

CNS Activity

Curator's Comment: Neuromidin (ipidacrine) has a direct stimulating effect on the conduct of the pulse along the nerve fibers, interneuronal and neuromuscular synapses of the CNS and peripheral nervous system.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Neuromidin

Approved Use

Unknown
Primary
Neuromidin

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Effects of NIK-247 on cholinesterase and scopolamine-induced amnesia.
1997-05
Antiamnesic and cholinomimetic side-effects of the cholinesterase inhibitors, physostigmine, tacrine and NIK-247 in rats.
1993-11-30
Patents

Patents

Sample Use Guides

Dose and duration of treatment is determined individually depending on the severity of the disease. Peripheral nervous system diseases: 10-20 mg; 1-3 times a day. The treatment is 1 to 2 months. To prevent myasthenic crises, severe violations of neuromuscular conduction briefly parenterally administered 1-2 ml (15-30 mg) Neuromidin 1,5% solution for injection, and then continue treatment tablets Neuromidin, the dose can be increased to 20-40 mg; 5 times a day.
Route of Administration: Other
In Vitro Use Guide
Unknown
Name Type Language
IPIDACRINE HYDROCHLORIDE
MI   WHO-DD  
Preferred Name English
IPIDACRINE MONOHYDROCHLORIDE
Common Name English
AMIRIDINE
Brand Name English
AMIRIDIN
Brand Name English
9-AMINO-2,3,5,6,7,8-HEXAHYDRO-1H-CYCLOPENTA(B)QUINOLINE HYDROCHLORIDE
Systematic Name English
Ipidacrine hydrochloride [WHO-DD]
Common Name English
1H-CYCLOPENTA(B)QUINOLIN-9-AMINE, 2,3,5,6,7,8-HEXAHYDRO-, HYDROCHLORIDE (1:1)
Systematic Name English
IPIDACRINE HYDROCHLORIDE [MI]
Common Name English
1H-CYCLOPENTA(B)QUINOLIN-9-AMINE, 2,3,5,6,7,8-HEXAHYDRO-, MONOHYDROCHLORIDE
Common Name English
NIK-247
Code English
Code System Code Type Description
PUBCHEM
6437859
Created by admin on Mon Mar 31 21:35:15 GMT 2025 , Edited by admin on Mon Mar 31 21:35:15 GMT 2025
PRIMARY
EPA CompTox
DTXSID00238003
Created by admin on Mon Mar 31 21:35:15 GMT 2025 , Edited by admin on Mon Mar 31 21:35:15 GMT 2025
PRIMARY
CAS
90043-86-0
Created by admin on Mon Mar 31 21:35:15 GMT 2025 , Edited by admin on Mon Mar 31 21:35:15 GMT 2025
PRIMARY
EVMPD
SUB34851
Created by admin on Mon Mar 31 21:35:15 GMT 2025 , Edited by admin on Mon Mar 31 21:35:15 GMT 2025
PRIMARY
MERCK INDEX
m776
Created by admin on Mon Mar 31 21:35:15 GMT 2025 , Edited by admin on Mon Mar 31 21:35:15 GMT 2025
PRIMARY Merck Index
FDA UNII
107D610372
Created by admin on Mon Mar 31 21:35:15 GMT 2025 , Edited by admin on Mon Mar 31 21:35:15 GMT 2025
PRIMARY
SMS_ID
100000128125
Created by admin on Mon Mar 31 21:35:15 GMT 2025 , Edited by admin on Mon Mar 31 21:35:15 GMT 2025
PRIMARY